709045-30-7Relevant articles and documents
Design and Development of a Series of Potent and Selective Type II Inhibitors of CDK8
Bergeron, Philippe,Koehler, Michael F. T.,Blackwood, Elizabeth M.,Bowman, Krista,Clark, Kevin,Firestein, Ron,Kiefer, James R.,Maskos, Klaus,McCleland, Mark L.,Orren, Linda,Ramaswamy, Sreemathy,Salphati, Laurent,Schmidt, Steve,Schneider, Elisabeth V.,Wu, Jiansheng,Beresini, Maureen
, p. 595 - 600 (2016)
Using Sorafenib as a starting point, a series of potent and selective inhibitors of CDK8 was developed. When cocrystallized with CDK8 and cyclin C, these compounds exhibit a Type-II (DMG-out) binding mode.
ANTHRANILIC ACID AMIDE DERIVATIVES AND THEIR PHARMACEUTICAL USE
-
Page 54, (2008/06/13)
The present invention relates to new anthranilic acid amide derivatives, processes for the preparation thereof, the application thereof in a process for the treatment of the human or animal body, the use thereof - alone or in combination with one or more